Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has a price-to-earnings ratio that is above its average at 16.60x. The stock has a 36-month beta value of 0.65. Opinions on the stock are mixed, with 7 analysts rating it as a “buy,” 6 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for ACAD is 166.02M, and at present, short sellers hold a 10.03% of that float. On June 18, 2025, the average trading volume of ACAD was 2.05M shares.
ACAD) stock’s latest price update
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has experienced a rise in its stock price by 2.98 compared to its previous closing price of 22.14. However, the company has seen a gain of 2.70% in its stock price over the last five trading days. businesswire.com reported 2025-06-17 that SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on June 6, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 187,664 shares of common stock and 89,582 restricted stock units (“RSUs”) to forty one new employees under Acadia’s 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ e.
ACAD’s Market Performance
Acadia Pharmaceuticals Inc (ACAD) has experienced a 2.70% rise in stock performance for the past week, with a 2.43% rise in the past month, and a 31.94% rise in the past quarter. The volatility ratio for the week is 2.43%, and the volatility levels for the past 30 days are at 1.81% for ACAD. The simple moving average for the last 20 days is 3.90% for ACAD’s stock, with a simple moving average of 32.17% for the last 200 days.
Analysts’ Opinion of ACAD
Many brokerage firms have already submitted their reports for ACAD stocks, with Deutsche Bank repeating the rating for ACAD by listing it as a “Buy.” The predicted price for ACAD in the upcoming period, according to Deutsche Bank is $35 based on the research report published on May 21, 2025 of the current year 2025.
Deutsche Bank, on the other hand, stated in their research note that they expect to see ACAD reach a price target of $22. The rating they have provided for ACAD stocks is “Hold” according to the report published on February 11th, 2025.
Guggenheim gave a rating of “Neutral” to ACAD, setting the target price at $20 in the report published on January 03rd of the current year.
ACAD Trading at 25.41% from the 50-Day Moving Average
After a stumble in the market that brought ACAD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.63% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACAD starting from Brege Laura, who sale 14,446 shares at the price of $21.78 back on Jun 04 ’25. After this action, Brege Laura now owns 15,095 shares of Acadia Pharmaceuticals Inc, valued at $314,634 using the latest closing price.
LAURA BREGE, the Director of Acadia Pharmaceuticals Inc, proposed sale 14,446 shares at $21.78 during a trade that took place back on Jun 04 ’25, which means that LAURA BREGE is holding shares at $314,638 based on the most recent closing price.
Stock Fundamentals for ACAD
Current profitability levels for the company are sitting at:
- 0.24 for the present operating margin
- 0.92 for the gross margin
The net margin for Acadia Pharmaceuticals Inc stands at 0.23. The total capital return value is set at 0.28. Equity return is now at value 37.24, with 23.03 for asset returns.
Based on Acadia Pharmaceuticals Inc (ACAD), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at 2.66.
Currently, EBITDA for the company is 100.16 million with net debt to EBITDA at -1.68. When we switch over and look at the enterprise to sales, we see a ratio of 3.67. The receivables turnover for the company is 8.76for trailing twelve months and the total asset turnover is 0.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.88.
Conclusion
To sum up, Acadia Pharmaceuticals Inc (ACAD) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
